Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model

Gynecol Endocrinol. 2016 Jun;32(6):492-7. doi: 10.3109/09513590.2015.1134478. Epub 2016 Jan 15.

Abstract

The aim of this study was to determine the effect of ursodeoxycholic acid (UDCA) treatment on a polycystic ovary syndrome (PCOS) rat model. Thirty-two female Wistar-Albino rats were randomly divided into four groups as follows - group 1: sham group (n: 8), group 2: letrozole-induced PCOS group (n: 8), group 3: letrozole-induced PCOS plus metformin-treated (500 mg/kg) group (n: 8) and group 4: letrozole-induced PCOS plus UDCA (150 mg/kg)-treated group (n: 8). Histopathologic examination of the ovaries, circulating estrone (E1), estradiol (E2), testosterone, androstenedione, glucose, insulin and lipid profiles were evaluated. Histopathologic examination results revealed that groups 3 and 4 had significantly lower cystic and atretic follicles compared to group 2. Besides, group 4 had significantly higher antral follicles than group 2 (8.5 ± 2.9 versus 5.4 ± 1.1; p: 0.001). Furthermore, total testosterone (4.9 ± 2.8 versus 8.8 ± 2.9; p= 0.004) and insulin levels were significantly lower in group 4 compared to group 2 (1.7 ± 0.08 versus 2.1 ± 0.5; p = 0.02). However, lipid parameters, E1, E2, glucose and HOMA-IR were comparable between the groups. Our study results demonstrated that UDCA therapy improves ovarian morphology and decreases total testosterone and insulin levels.

Keywords: Histopathology; polycystic ovary syndrome; treatment; ursodeoxycholic acid.

MeSH terms

  • Animals
  • Cholagogues and Choleretics / administration & dosage
  • Cholagogues and Choleretics / pharmacology*
  • Disease Models, Animal
  • Female
  • Ovary / drug effects*
  • Polycystic Ovary Syndrome / blood*
  • Polycystic Ovary Syndrome / drug therapy*
  • Rats
  • Rats, Wistar
  • Ursodeoxycholic Acid / administration & dosage
  • Ursodeoxycholic Acid / pharmacology*

Substances

  • Cholagogues and Choleretics
  • Ursodeoxycholic Acid